Next Article in Journal
A Review of Multidisciplinary Interventions in Atopic Dermatitis
Next Article in Special Issue
Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients
Previous Article in Journal
Pattern of Investigation Reflects Risk Profile in Emergency Medical Admissions
Previous Article in Special Issue
Current Cervical Carcinoma Screening Guidelines
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2015, 4(5), 1126-1155; doi:10.3390/jcm4051126

Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer

1
Research Institute of Pharmaceutical Science, Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul 151-742, Korea
2
ABION Inc., R&D Center, 9th Fl., HanWha Biz Metro Bldg., 242 Digital-ro, Guro-gu, Seoul 152-733, Korea
3
Department of Obstetrics and Gynecology, School of Medicine, Ewha Womans University, Seoul 158-710, Korea
*
Author to whom correspondence should be addressed.
Academic Editors: Jacqueline Guidry, Stephen K. Tyring and Christopher Downing
Received: 27 January 2015 / Accepted: 8 May 2015 / Published: 21 May 2015
(This article belongs to the Special Issue Clinical Advances of Human Papillomaviruses)
View Full-Text   |   Download PDF [687 KB, uploaded 21 May 2015]   |  

Abstract

Human papillomaviruses (HPVs) are small DNA viruses; some oncogenic ones can cause different types of cancer, in particular cervical cancer. HPV-associated carcinogenesis provides a classical model system for RNA interference (RNAi) based cancer therapies, because the viral oncogenes E6 and E7 that cause cervical cancer are expressed only in cancerous cells. Previous studies on the development of therapeutic RNAi facilitated the advancement of therapeutic siRNAs and demonstrated its versatility by siRNA-mediated depletion of single or multiple cellular/viral targets. Sequence-specific gene silencing using RNAi shows promise as a novel therapeutic approach for the treatment of a variety of diseases that currently lack effective treatments. However, siRNA-based targeting requires further validation of its efficacy in vitro and in vivo, for its potential off-target effects, and of the design of conventional therapies to be used in combination with siRNAs and their drug delivery vehicles. In this review we discuss what is currently known about HPV-associated carcinogenesis and the potential for combining siRNA with other treatment strategies for the development of future therapies. Finally, we present our assessment of the most promising path to the development of RNAi therapeutic strategies for clinical settings. View Full-Text
Keywords: HPV E6 and E7 oncogenes; siRNA pool; cervical cancer HPV E6 and E7 oncogenes; siRNA pool; cervical cancer
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Jung, H.S.; Rajasekaran, N.; Ju, W.; Shin, Y.K. Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer. J. Clin. Med. 2015, 4, 1126-1155.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top